Measuring and improving the quality of home care

Published Date: 13 Mar 2023

This document outlines goals for improving the quality of care in nursing homes and provides recommendations to support these efforts.

Read Full News

Todays Updates


AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women


AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know


CHEST 2026: Day 3 Recap — 6 Headlines to Know

What the Next Accelerated TMS Trial Should Test, With Jonathan Downar, MD Jonathan Downar, MD, PhD


Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH


The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio


One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis Marco Meglio


Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman


Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

Todays Updates


AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women


AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know


CHEST 2026: Day 3 Recap — 6 Headlines to Know

What the Next Accelerated TMS Trial Should Test, With Jonathan Downar, MD Jonathan Downar, MD, PhD


Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH


The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio


One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis Marco Meglio


Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman


Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chicken Broth Recall; Medicaid at Risk; Princess Kate Thanks Medical Staff

2.

Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.

3.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

4.

FDA Approves First CELMoD Drug for Multiple Myeloma

5.

In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot